HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/11/2019)... ... ... PracticeLink Live! Atlanta Physician Career Fair will take place Thursday, November 14, ... continue until 8:00 p.m. A free, optional seminar for job-seeking physicians, residents and fellows, ... Both the career fair and seminar are open to residents and fellows, as well ...
(Date:11/9/2019)... ... 08, 2019 , ... Mount Sinai Medical-Legal Partnership (MSMLP), an organization formed to ... free special education law and advocacy assistance to families and patients in need. The ... the work of contributions of Blaine (“Fin”) Fogg, who was a member of the ...
(Date:11/7/2019)... ... November 06, 2019 , ... An October 13 article ... United States. According to the article, while no U.S. state had an obesity rate ... over 20 percent obese. The article cites quite a few reasons for this rise, ...
(Date:11/7/2019)... Va. (PRWEB) , ... November 07, 2019 , ... Understanding ... – 3:00 p.m. EST, https://www.fdanews.com/understandudi , Are EU device and IV diagnostics ... to new EU device regulations —UDI — is ahead, and many device and diagnostics ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... label nutritional bar and functional powder solutions, recently achieved FSSC 22000 Certification of ... “We are pleased to share the news that we have achieved FSSC 22000 ...
Breaking Medicine News(10 mins):
(Date:11/11/2019)... Va. (PRWEB) , ... November 11, 2019 , ... The ... Bank of America health care practice POS, point of sale, website for providing the ... , The Naderi Center for Cosmetic Surgery Specialists uses advanced financial technology in their ...
(Date:11/11/2019)... ... 10, 2019 , ... Carex, a subsidiary of Compass Health ... which features over 600 available products and improved navigation with a stronger user ... health and wellness products, alongside, studies showing that over 90% of people ...
(Date:11/9/2019)... ... November 08, 2019 , ... WHAT:, Lillstreet Art Center ... a workshop for children to learn how to create clay candy creatures using pinch ... and shapes to personalize their pots in a sensory-friendly environment. , “We have ...
Breaking Medicine Technology:
Cached News: